SRRA Stock - Sierra Oncology, Inc.
Unlock GoAI Insights for SRRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | N/A | $300,000 | N/A | N/A | N/A |
| Gross Profit | N/A | $300,000 | N/A | N/A | N/A |
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A |
| Operating Income | $-94,662,000 | $-64,941,000 | $-66,992,000 | $-55,417,000 | $-42,619,000 |
| Net Income | $-94,659,000 | $-80,902,000 | $-88,275,000 | $-53,335,000 | $-42,015,000 |
| Net Margin | N/A | -26967.3% | N/A | N/A | N/A |
| EPS | $-7.14 | $-7.70 | $-30.30 | $-30.16 | $-33.68 |
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Visit WebsiteEarnings History & Surprises
SRRAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2022 | Aug 4, 2022 | $-0.95 | — | — | — |
Q2 2022 | May 6, 2022 | $-1.03 | $-1.33 | -29.1% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-1.54 | $-1.67 | -8.4% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-1.78 | $-2.10 | -18.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-1.61 | $-1.67 | -3.7% | ✗ MISS |
Q2 2021 | May 7, 2021 | $-1.60 | $-1.71 | -6.9% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-1.52 | $-1.63 | -7.2% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-1.64 | $-1.39 | +15.2% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-1.63 | $-1.58 | +3.1% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-2.74 | $-3.14 | -14.6% | ✗ MISS |
Q1 2020 | Mar 3, 2020 | $-3.16 | $-7.88 | -149.4% | ✗ MISS |
Q4 2019 | Nov 4, 2019 | $-8.40 | $-6.80 | +19.0% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-7.87 | $-8.00 | -1.7% | ✗ MISS |
Q2 2019 | May 8, 2019 | $-8.27 | $-6.80 | +17.8% | ✓ BEAT |
Q1 2019 | Feb 28, 2019 | $-8.27 | $-7.60 | +8.1% | ✓ BEAT |
Q4 2018 | Nov 8, 2018 | $-7.03 | $-8.40 | -19.5% | ✗ MISS |
Q3 2018 | Aug 9, 2018 | $-6.53 | $-6.40 | +2.0% | ✓ BEAT |
Q2 2018 | May 10, 2018 | $-8.53 | $-7.60 | +10.9% | ✓ BEAT |
Q1 2018 | Feb 27, 2018 | $-8.13 | $-8.00 | +1.6% | ✓ BEAT |
Q4 2017 | Nov 8, 2017 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Latest News
Frequently Asked Questions about SRRA
What is SRRA's current stock price?
What is the analyst price target for SRRA?
What sector is Sierra Oncology, Inc. in?
What is SRRA's market cap?
Does SRRA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SRRA for comparison